Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 9
Submit an article Journal homepage
3,286
Views
29
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

Luis FayadM. D. Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
,
Stephen M. AnsellMayo Clinic, Rochester, MN, USA
,
Ranjana AdvaniStanford Cancer Center, Stanford, CA, USA
,
Bertrand CoiffierCentre Hospitalier Lyon Sud, Pierre Benite, France
,
Robert StuartMedical University of South Carolina, Charleston, SC, USA
,
Nancy L. BartlettWashington University School of Medicine, St. Louis, MO, USA
,
Andres Forero-TorresUniversity of Alabama, Birmingham, AL, USA
,
Kazimierz KuliczkowskiSamodzielny Publiczny Szpital Kliniczny, Wroclaw, Poland
,
David BeladaCharles University in Prague, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
,
Edmund NgEdmund Ng Consulting LLC, Seattle, WA, USA
&
Jonathan G. DrachmanSeattle Genetics, Inc., Bothell, WA, USA
 show all
Pages 2569-2578 | Received 16 Jul 2014, Accepted 09 Jan 2015, Published online: 26 Feb 2015

References

  • Gisselbrecht C, Glass B, Laurent G, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol 2011;29(15 Suppl.): Abstract 8004.
  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
  • Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989;8:1403–1410.
  • van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997;9:330–337.
  • Gruss HJ, Herrmann F, Gattei V, et al. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997;24:393–422.
  • Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85:3378–3404.
  • Uckun FM, Gajl-Peczalska K, Myers DE, et al. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990;76:2449–2456.
  • Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1–13.
  • Law C-L, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331–8338.
  • Gowda AC, Zhao XB, Cheney C, et al. Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation. Blood 2005;106(Suppl. 1): Abstract 2966.
  • Drachman JG, Law C-L, Furman RR, et al. A humanized anti-CD40 monoclonal antibody (SGN-40) demonstrates antitumor activity in non-Hodgkin’s lymphoma: Initiation of a phase I clinical trial. J Clin Oncol 2005;23(16 Suppl.): Abstract 6572.
  • Lewis TS, McCormick RS, Emmerton K, et al. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res 2011;17:4672–4681.
  • Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371–4377.
  • De Vos S, Forero A, Ansell S, et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol 2014;7:44.
  • Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486–491.
  • Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Heamtology Am Soc Hematol Educ Program 2011:498–505.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Burington B, Yue P, Shi X, et al. CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med 2011;3:74ra22.
  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
  • Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
  • Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008;59:237–250.
  • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
  • Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 2008;143:607–621.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.